title: [Effectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer].
abstract: OBJECTIVE
  In this study we evaluated the activity and toxicity of a combination of 5-fluorouracil continuous infusion and vinorelbine as second or third line chemotherapy in metastatic breast cancer (MBC). PATIENTS AN METHODS: A total 24 patients who had received doxorrubicin and/or paclitaxel were included in this study. The regimen consisted in 5-fluorouracil 1 gr/m(2) BSA continuous infusion for 3 days and vinorelbine 30 mg/m(2) intravenous (IV) on day 1. The cycles were repeated every 21 days for 6 cycles.
  
  
  RESULTS
  Objective responses were recorded in 37.5% (12.5% complete remission). The median disease-free survival was calculated 6.33 +/- 8.12 months (CI 95% of 3.43 months). Toxicity was observed in 12.5% of the patients and no treatment related deaths were recorded.
  
  
  CONCLUSIONS
  The combination of 5-fluorouracil/vinorelbine at the dose administered is an effective regime in patients with MBC, with low toxicity and cost.
authors.affiliation: Centro Universitario contra el Cáncer, del Hospital Universitario, Universidad Autónoma de Nuevo León, México.
authors.forename: José Luis
authors.initials: JL
authors.lastname: González Vela
authors.forename: Jorge Martín
authors.initials: JM
authors.lastname: Sánchez Guillén
authors.forename: Sergio Arnoldo
authors.initials: SA
authors.lastname: Treviño Aguirre
authors.forename: David
authors.initials: D
authors.lastname: Hernández Barajas
authors.forename: William Orlando
authors.initials: WO
authors.lastname: Brito Villanueva
authors.forename: Eloy
authors.initials: E
authors.lastname: Cárdenas Estrada
authors.forename: Juan Francisco
authors.initials: JF
authors.lastname: González Guerrero
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine; D005472:Fluorouracil